Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
984314 | Research Policy | 2007 | 18 Pages |
Abstract
We explore a financial returns dimension of the exploration–exploitation dilemma. Using 1277 R&D announcements by 178 listed bio-pharmaceutical firms, we examine whether investors are myopic along the continuum of exploration (patenting and preclinical trials) to exploitation (human clinical trials and NDA). We find that investors respond positively at every stage, but there are differences between small and large firms. For small firms exploration is favored, provided it is focused. For large firms, there is value in both exploration and exploitation. Projects which are part of an alliance are no more likely to generate abnormal returns. Policy implications are discussed.
Related Topics
Social Sciences and Humanities
Business, Management and Accounting
Business and International Management
Authors
Peter Mc Namara, Charles Baden-Fuller,